Literature DB >> 23618358

Transcriptional regulation of the alpha-1 type II collagen gene by nuclear factor B/p65 and Sox9 in the chondrocytic phenotype of uterine carcinosarcomas.

Tsutomu Yoshida1, Miki Hashimura, Takeshi Kuwata, Toshihide Matsumoto, Erina Suzuki, Yuki Tazo, Hiroyasu Nakajima, Madoka Inukai, Makoto Saegusa.   

Abstract

Uterine carcinosarcomas (U-CSs) are considered monoclonal in origin, but little is known about the mechanisms for establishment of heterologous sarcomatous components. Here, we examine the functional roles of nuclear factor κB (NF-κB)/p65 and Sox9 in the transcriptional regulation of alpha-1 type II collagen (COL2A1), a hallmark of chondrogenesis, during morphologic change in the direction of the chondrocytic phenotype. In 32 cases of U-CS, both phosphorylated p65 and Sox9 expression were colocalized in Col2A1-positive sarcomatous components, particularly in cartilaginous elements, with strongly positive correlation (ρ = 0.72, P = .005). A positive association of Col2A1 expression between protein (immunohistochemistry) and messenger RNA (in situ hybridization) assays was evident in sarcomatous components, whereas 9 cases also showed distinct positive signals for the messenger RNA without protein expression in carcinomatous elements, probably through a posttranscriptional and/or posttranslational modulation mechanism. In the Ishikawa endometrial cancer line, overexpression of p65 could activate transcription of COL2A1 promoter-intron reporters through binding to specific NF-κB sites in the first intron, along with up-regulation of Sox9. Exogenous induction of Sox9 also caused an increase in transcription of COL2A1, in contrast to a repression of the p65-mediated COL2A1 transcription, suggesting the existence of a negative feedback loop. These data, therefore, suggest that NF-κB/p65 signaling, as well as Sox9, may contribute to changes in the morphology of U-CS cells toward the chondrocytic phenotype through modulation of COL2A1 transcription.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Clo2A1; NF-κB; Sox9; Uterine carcinosarcoma

Mesh:

Substances:

Year:  2013        PMID: 23618358     DOI: 10.1016/j.humpath.2012.12.019

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  6 in total

1.  Identification of biomarkers associated with partial epithelial to mesenchymal transition in the secretome of slug over-expressing hepatocellular carcinoma cells.

Authors:  Oğuzhan Karaosmanoğlu; Sreeparna Banerjee; Hülya Sivas
Journal:  Cell Oncol (Dordr)       Date:  2018-06-01       Impact factor: 6.730

Review 2.  The extracellular matrix alteration, implication in modulation of drug resistance mechanism: friends or foes?

Authors:  Ancuta Jurj; Calin Ionescu; Ioana Berindan-Neagoe; Cornelia Braicu
Journal:  J Exp Clin Cancer Res       Date:  2022-09-16

3.  FilGAP, a Rac-specific Rho GTPase-activating protein, is a novel prognostic factor for follicular lymphoma.

Authors:  Tatsuya Nishi; Hiroyuki Takahashi; Miki Hashimura; Tsutomu Yoshida; Yasutaka Ohta; Makoto Saegusa
Journal:  Cancer Med       Date:  2015-01-29       Impact factor: 4.452

Review 4.  The role of collagen in cancer: from bench to bedside.

Authors:  Shuaishuai Xu; Huaxiang Xu; Wenquan Wang; Shuo Li; Hao Li; Tianjiao Li; Wuhu Zhang; Xianjun Yu; Liang Liu
Journal:  J Transl Med       Date:  2019-09-14       Impact factor: 5.531

5.  Collagen family genes and related genes might be associated with prognosis of patients with gastric cancer: an integrated bioinformatics analysis and experimental validation.

Authors:  Kongyan Weng; Yinger Huang; Hao Deng; Ruixue Wang; Shuhong Luo; Hongfeng Wu; Jialing Chen; Mingjian Long; Wenbo Hao
Journal:  Transl Cancer Res       Date:  2020-10       Impact factor: 1.241

6.  Sulforaphane represses matrix-degrading proteases and protects cartilage from destruction in vitro and in vivo.

Authors:  Rose K Davidson; Orla Jupp; Rachel de Ferrars; Colin D Kay; Kirsty L Culley; Rosemary Norton; Clare Driscoll; Tonia L Vincent; Simon T Donell; Yongping Bao; Ian M Clark
Journal:  Arthritis Rheum       Date:  2013-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.